Update: JACC Intervention Publishes MIV Therapeutics Inc. (MIVT)'s VESTASYNC I Trial Preliminary Results
10/21/2008 8:23:04 AM
ATLANTA, GA--(Marketwire - October 21, 2008) - MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial. The peer-reviewed article titled "Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions - A First-In-Human Analysis of a Third Generation Drug-Eluting Stent (DES) System" appears in the October 21st edition of JACC and is available online at http://interventions.onlinejacc.org/.
comments powered by